Robin Low, CEO & Founder of Areteon, Singapore

Case study: Areteon, Singaporean company working to solve the global AMR problem

Emily Event News Leave a Comment

Drug-resistant microbial is one of the hottest topics of the 21st century. With the potential to cause nearly $100 trillion in damage to the world’s health and economy, the issue of infections untreatable by modern antibiotics is one that leaves many concerned and looking for solutions. But did you know a Singapore-based biotech company is part of effort to prevent …

Pictured Erick Co, CSO of Formosa Pharmaceutical during the acquisition of Activus Pharma, August 2017.

Expanding from a pure API provider to new drug developer: Formosa is growing

Emily Event News Leave a Comment

Pictured Erick Co, CSO of Formosa Pharmaceutical during the acquisition of Activus Pharma, August 2017.  Formosa Pharma, Taiwan is a subsidiary of globally-recognized API provider, Formosa Laboratories. This preclinical and clinical stage biopharmaceutical company has a strong focus on anti-infective and oncology indications. Having recently acquired Activus Pharma and its Activus Pure Nanoparticle Technology Platform (APNT), Formosa Pharmaceuticals is growing …

Marc Voigt, CEO of Immutep (Previously Prima Biomed) speaking at Phar-East 2018, Singapore, 28Feb-2Mar

10 minutes with Marc Voigt, CEO of Immutep (Previously known as Prima Biomed)

Emily Event News Leave a Comment

Prima Biomed was originally built on CVac, a therapeutic cancer vaccine. With its recent shift to embrace multiple products, the company has decided to rebrand itself to Immutep, named after a subsidy acquired in 2014. Leading the company is Marc Voigt, who will join us at Phar-East 2018 to speak about their vision of the next big immune checkpoint in the immunotherapy race. …